PROTHENA CORP PUBLIC LTD CO (PRTA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$330.3M
Cash & Equivalents
$28.9M
Quarterly Burn Rate
$484M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07174310 | A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson'... | PHASE3 | Recruiting | 900 |
| NCT04777331 | A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | PHASE2 | Active Not Recruiting | 586 |
| NCT03100149 | A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | PHASE2 | Active Not Recruiting | 316 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.